🚨 #ESMO26 | II期 TQB2102-II-04 用于一线 HER2+ 胃/胃食管结合部癌。
TQB2102 (HER2 ADC) + benmelstobart + 卡培他滨：
🔹 ORR 84.2%（6 mg/kg 时 95.8%）
🔹 DCR 100%
🔹 mPFS 11.0 个月
显示出良好的疗效且安全性可控。计划开展 III 期试验。
#GIOnc @OncoAlert @myESMO
320 浏览 · 8 赞 · 5 转发 · 0 回复
Early clinical antitumor activity of VRN101099 across diverse HER2-mutants in solid tumors
https://esmocongress.esmo.orgHealth-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgEfficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgGene-expression profiling of HR+/HER2- breast cancers arising in germline BRCA1/2 mutation carriers
https://esmocongress.esmo.org来源：Vilma P. Barcia MD, PhD, MSc · x.com